Published in final edited form as:

J Cancer Surviv. 2016 February ; 10(1): 21–30. doi:10.1007/s11764-015-0448-9.

Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case control study

Patricia Sheean, PhD, RD,

Post-doctoral research associate, Loyola University Chicago, Marcella Niehoff School of Nursing, Health Sciences Campus, 2160 South First Avenue, Building 105, Room 2582, Maywood, IL 60153, 708-216-0344 (work)

Huifang Liang, MD, PhD,

Principal Scientist Pharmacoeconomics, Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL 60015

Linda Schiffer, MS, MPH,

Research Data Analyst, University of Illinois at Chicago, Department of Medicine, Section for Health Promotion Research, 1747 West Roosevelt Road, Room 558, MC 275, Chicago, IL 60608

Claudia Arroyo, MPH,

University of Illinois at Chicago, Department of Medicine, Section for Health Promotion Research, 1747 West Roosevelt Road, Room 558, MC 275, Chicago, IL 60608

Karen Troy, PhD, and

Assistant Professor, Biomedical Engineering, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609

Melinda Stolley, PhD

Associate Professor, University of Illinois at Chicago, Department of Medicine, Section for Health Promotion Research, 1747 West Roosevelt Road, MC 275, Chicago, IL 60608

Patricia Sheean: psheean1@luc.edu; Huifang Liang: huifang.liang@takeda.com; Linda Schiffer: lschiff@uic.edu; Claudia Arroyo: carroy5@uic.edu; Karen Troy: ktroy@wpi.edu; Melinda Stolley: mstolley@uic.edu

Abstract

Purpose—Osteoporosis increases the risk of fracture and is often considered a late effect of breast cancer treatment. We examined the prevalence of compromised bone health in a sample of exclusively African-American (AA) breast cancer survivors since bone mineral density (BMD) varies by race/ethnicity in healthy populations.

Methods—Using a case-control design, AA women in a weight loss intervention previously diagnosed and treated for Stage I-IIIa breast cancer were matched 1:1 on age, race, sex and BMI with non-cancer population controls (n=101 pairs) from NHANES. Questionnaires and dual energy x-ray absorptiometry (DXA) scanning were completed and participants were categorized

Conflict of Interests: The authors have no conflict of interests to disclose regarding the conduct and report of this work.

as having normal bone density, low bone mass or osteoporosis using the WHO definition for femoral neck T-scores.

Results—The majority of these overweight/obese survivors were 6.6 ($\pm$ 4.7) years post-diagnosis, had Stage II (n=46) or Stage III (n=16) disease, and treated with chemotherapy (76%), radiation (72%) and/or adjuvant hormone therapies (45%). Mean femoral neck BMD was significantly lower in cases vs. matched non-cancer population controls (0.85 ± 0.15 vs. 0.91 ± 0.14 g/cm², respectively; $p=0.007$). However, the prevalence of low bone mass and osteoporosis was low and did not significantly differ between groups (n=101 pairs; $p=0.26$), even when restricted to those on adjuvant hormone therapies (n=45 pairs; $p=0.75$). Using conditional logistic regression, controlling for dietary factors and education, the odds of developing compromised bone health in AA breast cancer survivors was insignificant (OR 1.5, 95% CI 0.52, 5.56).

Conclusions—These null case-control findings challenge the clinical assumption that osteoporosis is highly prevalent among *all* breast cancer survivors, providing foundational evidence to support differences by race/ethnicity and body weight.

Implications for cancer survivors—Routine bone density testing and regular patient-provider dialogue is critical in overweight/obese AA breast cancer survivors to ensure that healthy lifestyle factors (e.g., ideal weight, regular weight-bearing exercises, dietary adequacy of calcium and vitamin D) support optimal skeletal health.

Keywords

bone health; osteoporosis; African-American; breast cancer; survivor; vitamin D; NHANES

Introduction

Advances in breast cancer diagnosis and treatment have resulted in improved survival from this potentially devastating disease [1]. Consequently, this progress has highlighted the need to address the detection and management of multiple chronic disease conditions as these survivors age. Maintaining skeletal integrity has long been a priority in older populations, since major osteoporotic fractures are associated with significant increases in morbidity and mortality.[2] Based on recent data from the United States (US) census and the National Health and Nutrition Examination Survey (NHANES), it is estimated that 99 million adults in the US are 50 years of age and of these, 53.6 million (~54%) have osteoporosis or low bone mass (previously known as *osteopenia*). [3] The occurrence of osteoporosis and low bone mass increases with age, especially after the fifth decade of life; [4] however, it is also more frequent among women and varies by race/ethnicity. The prevalence of osteoporosis and low bone mass for older US women (> 50 years of age) is 15.4% and 51.4%, respectively, which is highest for Mexican American women (20.4% and 47.8%, respectively) and lowest for African-American (AA) women (7.7% and 36.2%, respectively.) [3] Women treated for breast cancer often experience premature ovarian failure, are prescribed estrogen deprivation therapies and receive cytotoxic chemotherapies that result in higher bone turnover and bone loss [5, 6]. As a result, osteoporosis is prevalent in 20–30% of breast cancer survivors [7–10], and considered a late-effect of treatment. However, these studies included predominantly European-American women and analyzed

AA women in aggregate, despite the known differences in osteoporosis by race/ethnicity in healthy populations [11]. Therefore, the bone health of AA breast cancer survivors remains largely unknown.

Vitamin D, a fat-soluble vitamin, is best recognized for its role in calcium absorption in the gastrointestinal tract and maintaining serum calcium and phosphate concentrations to support bone mineralization. Sunlight exposure constitutes the primary source of vitamin D₃ since dietary sources are derived from foods with limited consumption (e.g., fortified milk, salmon, tuna, and mackerel) [12]. Because darker skin pigmentation is associated with decreased ability to absorb ultraviolet light, reports of vitamin D deficiency among AA breast cancer survivors are not surprising [13, 14]. When considered in the context of adjuvant hormonal breast cancer treatment, bone disease may be a highly prevalent, yet underappreciated condition among AA breast cancer survivors. Therefore, the primary purpose of this case-control study was to examine the prevalence of compromised bone health in an exclusively AA group of breast cancer survivors and compare them to matched non-cancer population controls, taking into account important body weight, lifestyle factors and the influence of breast cancer treatments. We hypothesized that osteoporosis would be greater in our breast cancer survivors, especially among women prescribed adjuvant hormonal therapies. A secondary purpose was to provide clinicians preliminary evidence to support and to tailor pharmacological and non-pharmacological care plans for bone health in this population.

METHODS

Breast cancer participants

Participants comprised a subsample of overweight/obese AA women recruited as part of larger, on-going randomized controlled trial (R01CA154406) targeting AA breast cancer survivors from lower-income communities within Chicago, Illinois; a regional area prone to health disparities and higher breast cancer mortality [15]. The overarching goal of the larger trial was to determine the effectiveness of a behavioral weight loss program developed by and for AA breast cancer survivors. Women were recruited from 2011–2013 through the University of Illinois (UIC) Hospital and Health Sciences Cancer registry, oncologist referrals, community events, neighborhood leaflet distributions, posted and on-line advertisements and word-of-mouth. Eligible adult women: 1) self-identified as Black or AA females; 2) were diagnosed with Stage I–III invasive breast carcinoma; 3) completed treatment (surgery, chemotherapy and/or radiation) at least six months *prior to* recruitment (ongoing adjuvant hormonal therapies acceptable); and 4) were overweight (body mass index (BMI) 25.0–29.9 kg/m²) or obese (BMI >30.0 kg/m²). Women were excluded if they were: 1) planning on moving out the community during the study, 2) deemed unable to engage in physical activity by their primary care physician (e.g., history of emphysema, extreme dyspnea on exertion, wheelchair or walker dependent,) 3) currently pregnant, less than 3 months post-partum or anticipating pregnancy, 4) taking prescribed weight loss medications, 5) enrolled in a formal weight loss program requiring special foods, or 6) suffering from psychiatric conditions that precluded study participation. The study was approved by the UIC Institutional Review Boards.

Women interested in the weight loss intervention were screened for initial eligibility over the telephone. Eligible women were then scheduled for a baseline interview, where the study was described in further detail, informed consent was obtained, and questionnaires were completed. Approximately, one month within the baseline interview, women returned for anthropometric measures and dual energy x-ray absorptiometry (DXA) completion. For the cases, all laboratory and bone density information was collected at baseline prior to participating in the weight loss intervention.

Matched non-cancer population controls

A dataset of women was created from the 2007–2010 National Health and Nutrition Examination Surveys (NHANES) for comparison by using 1:1 matching on sex, age, race and BMI.[16]

Eligibility and matching—Women in the 2007–2010 NHANES datasets who were free of cancer, had complete data on age, height, weight, femoral BMD, 24-hour dietary recall data and information on disease history (hypertension, diabetes), education and insurance were identified. Matching criteria included age (within 1 year), sex, race and BMI (within 2 kg/m²), based on their known relationship to bone health. To increase precision and to maximize sample size, BMI was matched within 2 kg/m² vs. matched by weight categories (e.g., overweight, class I, II, III obesity). All records that met the matching criteria were selected. The record having the same sex, race, and minimum age and BMI difference with a breast cancer case was selected as the control. To guarantee no duplication of non-cancer controls, the non-cancer record was deleted after being selected from the NHANES dataset and no longer available for further matching. The dataset with non-cancer population controls was vertically merged with the breast cancer dataset prior to analyses.

Study variables

The following variables were collected for all cases and controls, unless otherwise specified.

Demographics—Demographic parameters included age, sex, race, level of education (high school or less, some college, college graduate or graduate degree), employment (paid work, not working, out of work or other) and health insurance (none, public, private or other). Self-reported co-morbid conditions were also collected, including hypertension and diabetes.

Additionally, cases self-reported menopausal status, breast cancer stage, date of diagnosis and breast cancer treatments [e.g., chemotherapy (yes/no), radiation (yes/no), current or previous endocrine therapies (serum estrogen receptor modulators (SERMS) or AIs). Types and doses of chemotherapy, as well as length of time on adjuvant endocrine therapies were not ascertained. If a breast cancer participant was unsure of her breast cancer stage, her oncologist was contacted to verify that she was not Stage 0 or IV, which precluded further participation.

Anthropometrics—Height and weight were measured by trained personnel using standardized, calibrated equipment and quality assurance measures were employed in each

study. Measurements were recorded to the nearest 0.1 cm or 0.1 kg, respectively. Height and weight were used to calculate BMI (kg/m^2) which was used to classify overweight and obesity.

Diet assessment—Breast cancer participants completed the Block 2005 Food Frequency Questionnaire (FFQ); a validated [17], 110-item dietary assessment tool administered by trained personnel to assess dietary intake and supplement use. FFQs were processed by Nutrition Quest (Berkeley, CA) to procure habitual dietary intakes of energy, calcium and vitamin D. Calcium and vitamin D intake were quantified from food and beverage sources and in the form of dietary supplements. For the matched non-cancer population controls, two 24-hour diet recalls were collected by NHANES interviewers trained in the USDA's automated multiple-pass method. Data were collected in 5 standardized steps to accurately capture detailed descriptions of the amount, type, time and location of food consumption, including intake of specific dietary supplements.[18]

Bone density—Quantifications of femoral neck BMD were obtained using DXA; the reference standard for describing osteoporosis.[19] The left hip was scanned on all participants, unless otherwise specified. BMD was ascertained on all breast cancer participants using the iLunar device (GE, software version 13.6), while NHANES participants completed femur scans using a Hologic QDR 4500A fan-beam densitometer (Discovery, software version 12.4.) For quality control purposes, DXA machines were regularly calibrated and scans were performed and analyzed by trained technicians and study personnel blind to study outcomes. Although DXA devices from all manufacturers have inherently high accuracy and precision in quantifying bone density, BMD quantifications will not be identical across manufacturers due to differences in calibration techniques.[20] Therefore, to account for differences in femoral neck BMD between DXA manufacturers, the conversion equations set forth by Lu et al [21] and endorsed by the GE manufacturer (personal communication) for femoral neck and femoral total femur were applied.

Statistical analyses

Means and standard deviations (SDs) were used to describe normally and nonnormally distributed variables. Frequencies were used as descriptors for categorical variables. A paired t-test, or Wilcoxon signed rank test was used for continuous variables and the McNemar's test or a Mantel-Haenszel matched-pairs analysis test was used for categorical variables. The following WHO diagnostic criteria were used to classify bone health for all participants: osteoporosis [a BMD value that lies 2.5 standard deviations (SD) or more below the average value for young healthy women (a T-score of <-2.5 SD)]; low bone mass [a BMD value between 1.0–2.5 SD below mean of young adult reference group (T-score -1.0 to -2.5 SD)]; and normal bone mass (T-score > -1.0 SD)]. As recommended by the WHO, femoral BMD values of 20–29 year-old healthy, non-Hispanic White women from NHANES III 1988–94 were used to calculate femoral neck T-scores for all breast cancer cases and matched non-cancer population controls. [22, 19]

Conditional logistic regression was used to assess whether having breast cancer was a risk factor for osteoporosis and low bone mass (a T-score of -1.0), controlling for the well-

known confounders of age, sex, race, and BMI (through matching). In addition, dietary intakes of calcium (calcium intake 1200 mg/d) and vitamin D (vitamin D intake 600 IU/d) were included since these specific cut-points are considered sufficient to support bone health for ~98% of the population by the Institute for Medicine.[12] The potential confounding effect of educational level (college degree yes/no) was also explored. Based on previous studies demonstrating adverse relationships with adjuvant hormone therapies and bone health [23, 24], women who had been prescribed AIs at any time (current or prior use), received tamoxifen prior to menopause or tamoxifen prior to 45 years of age were compared to their sex, age, race and BMI-matched counterparts. Conditional logistic modeling for this subanalysis was approached similarly to the primary outcome analyses.

Although strong correlations between nutrient data obtained from FFQs and 24-hour dietary recall have been reported, inconsistencies remain [25]. To address concerns regarding differences in nutrient intake by dietary assessment methodology, linear trends in femoral BMD were assessed across quartiles of total calcium and vitamin D intake using FFQ and 24-hour recall dietary data. All statistical analyses were performed using SAS (version 9.2, 2009, SAS Institute, Cary, NC.) and a p value 0.05 was used to denote statistical significance.

RESULTS

A total of 141 women were screened for the weight loss intervention. Of these, 8 withdrew, 10 did not complete the initial interview, 11 were interviewed but unable to participate and 1 did not receive physician approval, leaving 111 breast cancer participants for inclusion in this ancillary study. When all matching criteria were applied to obtain population controls, data on 101 pairs were available. A general description of the matched participant characteristics are reported in Table 1. Breast cancer survivors had achieved higher levels of education ($p=0.0002$), were more likely to be out of work ($p=0.03$) but more often had insurance coverage ($p=0.01$). The average breast cancer survivor was diagnosed at 47.7 (± 9.6) years of age and was 6.6 (± 4.7) years post-diagnosis at the time of enrollment. The majority of the women had Stage II ($n=46$) or Stage III ($n=16$) disease, and 76% and 72% had received chemotherapy and radiation therapy, respectively.

Table 2 describes the bone health characteristics between the breast cancer survivors and their matched non-cancer population controls ($n=101$ pairs.) Breast cancer survivors had significantly lower femoral neck BMD ($p=0.007$) and femoral neck T-scores ($p=0.007$) than controls. Despite these differences, no significant differences were observed in the prevalence of low bone mass or osteoporosis ($p=0.263$) between groups. Specifically, the prevalence of osteoporosis was 1% vs. 0%, while the prevalence of low bone mass was 16% vs. 10% in cases vs. controls, respectively. Energy intake and dietary intake of calcium were significantly higher among the breast cancer survivors compared to the matched non-cancer population controls ($p=0.007$ and $p=0.05$, respectively.) While supplemental vitamin D intake was significantly higher in the controls ($p=0.01$), there were no differences in the average total vitamin D intake between groups. Conditional logistic regression modeling showed that AA women who had breast cancer were not more likely to have compromised bone health compared to age, sex, race and BMI matched non-cancer population controls

(crude OR 1.86, 95% CI 0.74, 4.66). This relationship did not change after controlling for calcium intake >1200 mg/d and vitamin D intake >600 IU/d (OR 1.86, 95% CI 0.72, 4.84), nor did it change after controlling for education (college degree; OR 1.53, 95% CI 0.52, 5.56).

Table 3 reflects the subanalyses conducted on women who had received adjuvant hormone therapies (n=45 pairs.) No differences between groups were found for femoral neck BMD, total femur BMD or femoral neck T-scores. Specifically, the prevalence of osteoporosis was 0% vs. 0%, while the prevalence of low bone mass was 18% vs. 13% in cases vs. controls, respectively (p=0.754). Total calcium intake was higher in the breast cancer survivors vs. the matched non-cancer population controls (p=0.03) due to significantly higher intakes of supplemental calcium intake (p=0.01). Similar trends were seen in the breast cancer cases for vitamin D intake. Conditional logistic regression modeling showed that AA women breast cancer survivors on adjuvant hormone therapies were not more likely to have compromised bone health compared to age, sex, race and BMI matched non-cancer population controls (crude OR 1.50, 95% CI 0.42, 5.32). The relationship remained insignificant after controlling for calcium intake >1200 mg/d and vitamin D intake >600 IU/d (OR 1.16 (95% CI 0.24, 5.59), and after additionally controlling for education (college degree; OR 3.25, 95% CI 0.28, 37.58).

Discussion

Osteoporosis is associated with age, hormone-related changes in bone microarchitecture, and decreased BMD. These increase the propensity for fracture resulting in long-term disability, morbidity and mortality, especially among breast cancer survivors.[26] The widely cited investigation by Chen et al, which compared bone density and rate of changes in BMD between breast cancer survivors and women without cancer, showed that osteoporosis occurred in 27.2% of the survivors vs. 19.4% of women in the reference group over an average of 6.7 years. Among the survivors, bone loss was: 1) most likely to occur within the first few years following breast cancer treatment, 2) significantly associated with chemotherapy, and 3) more prominent in women diagnosed pre-menopausally. [7] The prevalence of osteoporosis in other studies of female breast cancer survivors has been reported to be 20–22%. [8–10] Our results indicate that despite suboptimal mean intakes of calcium and vitamin D and the frequent use of chemotherapy and adjuvant hormone therapies, the prevalence of osteoporosis was only 1% which was similar to sex, age, race and BMI non-cancer population controls. On average, our participants had completed their initial breast cancer treatment 6.6 years prior to the time of enrollment; a similar time period to Chen et al. [7] Therefore we believe this time frame was sufficient to observe the outcome of interest, if it were to occur. We speculate that the prevalence estimates are higher in other studies due to the inclusion of predominantly white women who had a substantially lower body weight and BMI. The average BMI of our study participants was 35.8 kg/m², whereas participants in the Twiss et al [9] and Lindsey et al [8] studies had a BMI of 27.3 kg/m². In the more recent investigation by Friedman et al [10], 72% of the participants had a BMI less than 30 kg/m² and only 18% of their study population was ‘nonwhite.’ Further, although the mean calcium and vitamin D intake was considered “suboptimal” for the cases and controls in our study, a greater number of breast cancer survivors reported “optimal” calcium (>1200

mg/d) and vitamin D intake (>600 mg/d) compared to the non-cancer population controls (32% vs. 16%, respectively; $p=0.02$ and 20% vs. 12%, respectively, $p=0.12$). These nutrients are considered essential to optimal bone health [12] and may help to further explain the lower occurrence of compromised bone health in our study sample compared to others.

Although the mechanisms are not fully understood, breast cancer treatment can impact bone health in a multitude of ways, beginning with acute deteriorations in important lifestyle behaviors (e.g. diet and physical activity) that provide essential nutrients and favorable stress on the bone. In addition, women frequently experience temporary or permanent premature ovarian failure induced by chemotherapy, oophorectomy, or gonadotropin releasing hormone (GnRH) agonists, resulting in prolonged periods of hypoestrogenemia. This estrogen deficiency leads to increased bone resorption and rapid bone loss. [27] Further, in women whose tumors express estrogen (ER) or progesterone (PR), adjuvant endocrine therapies are prescribed to induce estrogen blockade or inhibit estradiol production. In previous trials comparing the efficacy of AIs to tamoxifen in early hormone-receptor positive breast cancer, higher fractures rates were observed among women in the AI arms, revealing important negative implications of these drugs [28, 29]. Because fractures were reported as adverse events, no detailed information was provided. Subsequent bone sub-studies on these cohorts, however, revealed decreases in BMD in the lumbar spine (-6.08% vs. $+2.77\%$, $p<.0001$) and total hip (-7.24% vs. $+0.74\%$, $p<.0001$) from baseline to 5 years in patients treated with anastrozole (a non-steroidal AI) vs. tamoxifen, respectively. Changes were most pronounced within the first two years of therapy. [23] Additional reports found that anastrozole was associated with increases in bone turnover, whereas tamoxifen was associated with decreases in turnover. [30] Further, Lonning et al evaluated the potential detrimental effects of exemestane (a steroidal AI) on BMD in 147 postmenopausal women with early breast cancer using a randomized (double-blind), controlled design.[24] Rates of BMD loss on an annual basis were 2.17% vs. 1.84% in the lumbar spine ($p=0.56$) and 2.72% vs. 1.48% in the femoral neck ($p=0.02$) in the exemestane and placebo arms, respectively. Similarly, Gonnelli et al observed decreases in BMD in postmenopausal women randomized to the exemestane group vs. continuation of tamoxifen group.[31] Although these data strongly suggest that both steroidal and non-steroidal AIs detrimentally impact bone, body weight was inconsistently controlled for and race/ethnicity was not described. Conventionally, AA women are underrepresented in breast cancer trials; therefore, the implications of these therapies on overweight/obese AA breast cancer survivors cannot be readily determined. Our data continue to suggest that these therapies may have limited impact on the bone health of overweight/obese AA breast cancer survivors or that the negative impact of these therapies may be offset by the increased bone mass associated with higher body mass.

It is well accepted that race/ethnicity is an established mediator of bone health and BMD is consistently higher in AA vs. white women and across the body weight spectrum. [32–34, 4] Previous investigators have theorized that greater muscle mass [35], resistance to bone-resorbing action of parathyroid hormone (PTH) [36], and lower concentrations of osteocalcin [37] reflective of reduced bone turnover may be responsible for these race/ethnicity differences. More recently, however, Powe et al. demonstrated that AA community dwelling adults had significantly lower levels of vitamin D binding protein compared to

their white counterparts, which were largely explained by genetic polymorphisms in the vitamin D-binding protein gene (rs7041 and rs4588). Additionally, these authors suggested that despite significant differences in serum concentrations of 25(OH)D, bioavailable 25(OH)D levels were equivalent between races and thus, these findings help to explain the lack of association between low 25(OH) D levels and compromised bone health in AAs in the general population [38]. It is well known that BMI is positively associated with higher BMD [39]; however, osteoporosis is considered a late effect of breast cancer treatment, regardless of BMI. Our results indicate that overweight and obese AA women are partially protected from this risk, making a unique contribution to this growing body of literature. Current prevalence estimates of skeletal health stratify by sex, race and decade of life, not BMI or body weight. [3] As a result of matching BMI within 2 kg/m², we may have artificially lowered the overall prevalence of compromised skeletal integrity in our study sample. More importantly, however, these study findings reinforce the importance of controlling for race/ethnicity and body weight for all future investigations examining bone health.

This case-control study is not without limitations, and several factors merit consideration. First, it is well known that body weight and body mass index are positively associated with BMD and this study did not include AA women with normal BMI (18.5–24.9 kg/m²). Considering that population estimates classify 77% of AA women as overweight or obese [40] and that adverse body composition changes are associated with breast cancer treatment (e.g., weight gain and increased adiposity) [41], these findings likely have broad applicability for the majority of AA breast cancer survivors. Second, BMD was generated from two different DXA manufacturers in cases vs. matched non-cancer population controls; thereby requiring the application of translational equations for validated comparisons of femoral BMD and T-score calculations.[21] To further unify these BMD comparisons, all T-scores were calculated using the same referent population and BMD values were not standardized to avoid converting all data to a third metric that has limited clinical utility. Third, menopausal status, date of diagnosis, breast cancer treatments and adjuvant hormonal therapy use was self-reported, and therefore, prone to the inherent biases and misclassifications of such reports. It is possible that women could have misreported dates or the use and type of these treatments. In addition, the length of time on various adjuvant therapies was not ascertained. Fourth, even though participants were recruited from neighborhoods of varying socioeconomic status, many of our participants were well-educated, and all had the desire, motivation and physical abilities to enroll in a weight loss program. While this may present confines on the generalizability of these findings for all AA breast cancer survivors, education (a strong proxy of socioeconomic status) was not a significant contributor in the primary outcome models. Fifth, the time of study recruitment (2011–2013) and the time controls were ascertained from NHANES (2007–2010) do not directly align. Although significant shifts in the prevalence of obesity and osteoporosis could occur, adverse changes in these health conditions have not been observed in the previous decade [4, 42]. Sixth, the differences in macro- and micronutrient intake between groups may be explained by the use of two different dietary assessment methodologies. The failure to detect a linear trend for BMD across quartiles for calcium and vitamin D within these respective instruments minimizes the effects of these various methodologies on outcome.

Finally, this study is only a “snap shot” assessment of bone health in these overweight/obese women. Studies of longer duration are needed.

Conclusions

Current evidence suggests that women who survive their breast cancer are at an elevated risk for bone disease; however, our case-control findings challenge these clinical assumptions and suggest potential differences by race/ethnicity and body weight. Despite several clinical factors that would predispose breast cancer survivors to bone disease, the prevalence of osteoporosis and low bone mass in this sample was relatively low overall and comparable to race, sex, age and BMI matched non-cancer population controls from NHANES. Due to the lack of knowledge regarding the bone health of AA breast cancer survivors, this study makes a novel contribution to the survivorship literature and underscores several important clinical points. First, routine bone density screening is necessary to ensure bone integrity over time and to prevent unnecessary prescription and/or over-the-counter medications (e.g., bisphosphonates, dietary supplements.) Similar to studies in healthy AA women [43], several of our participants stated that had not undergone bone health screening, and some reported receiving bisphosphonates. These practices are not consistent with the recommendations of the National Comprehensive Cancer Network on bone health. [44] Second, future trials evaluating bone health endpoints need to intensify recruiting efforts to specifically include AA breast cancer survivors for appropriate risk stratification. Third, while bisphosphonates are efficacious for the prevention and/or treatment of osteoporosis [45], the importance of non-pharmacologic behaviors (e.g., regular weight-bearing exercises, physical activity, avoidance of tobacco products, limited alcohol consumption and dietary adequacy of calcium and vitamin D) merit regular dialogue between health care providers and patients. [46] The preventative role of these behaviors should be explained in the context of bone health during the development of individually tailored survivorship care plans and should be appropriately considered (e.g., data collection and analyses) in future research efforts, especially as these minority women age.

Acknowledgments

Funding: National Institute on Aging, Midwest Roybal Center for Health Promotion and Translation (P30AG022849); National Cancer Institute, Moving Forward (R01CA154406); National Cancer Institute, Cancer Education and Career Development Program (R25CA057699-18)

Abbreviations used

AA	African-American
AIs	aromatase inhibitors
BMI	body mass index
BMC. bone mineral content	BMD, bone mineral density , DXA, dual energy x-ray absorptiometry
IOM	Institute of Medicine

IU	International Units
NCHS	National Center for Health Statistics
NOF	National Osteoporosis Foundation
SERMs	selective estrogen receptor modulators
SD	standard deviation
WHO	World Health Organization

References

1. National Cancer Institute. SEER Cancer Statistics Review 1975–2010. National Cancer Institute; http://seer.cancer.gov/csr/1975_2010/browse_csr.php?sectionSEL=4&pageSEL=sect_04_table_10.html [Accessed December 23 2013]
2. Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. *Nat Rev Endocrinol*. 2014; 10(10):592–602.10.1038/nrendo.2014.125 [PubMed: 25091729]
3. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res*. 2014; 29(11):2520–6.10.1002/jbmr.2269 [PubMed: 24771492]
4. Looker AC, Melton LJ 3rd, Harris TB, Borrud LG, Shepherd JA. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. *J Bone Miner Res*. 2010; 25(1):64–71.10.1359/jbmr.090706 [PubMed: 19580459]
5. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. *Oncologist*. 2008; 13(2):187–95.10.1634/theoncologist.2007-0152 [PubMed: 18305064]
6. Winters-Stone KM, Schwartz A, Nail LM. A review of exercise interventions to improve bone health in adult cancer survivors. *J Cancer Surviv*. 2010; 4(3):187–201.10.1007/s11764-010-0122-1 [PubMed: 20373041]
7. Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. *Cancer*. 2005; 104(7):1520–30.10.1002/cncr.21335 [PubMed: 16110508]
8. Lindsey AM, Gross G, Twiss J, Waltman N, Ott C, Moore TE. Postmenopausal survivors of breast cancer at risk for osteoporosis: nutritional intake and body size. *Cancer nursing*. 2002; 25(1):50–6. [PubMed: 11838720]
9. Twiss JJ, Waltman N, Ott CD, Gross GJ, Lindsey AM, Moore TE. Bone mineral density in postmenopausal breast cancer survivors. *J Am Acad Nurse Pract*. 2001; 13(6):276–84. [PubMed: 11930870]
10. Friedman CF, DeMichele A, Su HI, Feng R, Kapoor S, Desai K, et al. Vitamin d deficiency in postmenopausal breast cancer survivors. *Journal of women's health*. 2012; 21(4):456–62.10.1089/jwh.2011.3009
11. Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. *Clin Orthop Relat Res*. 2011; 469(7):1891–9.10.1007/s11999-011-1863-5 [PubMed: 21431462]
12. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.
13. Neuhouwer ML, Sorensen B, Hollis BW, Ambis A, Ulrich CM, McTiernan A, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. *The American journal of clinical nutrition*. 2008; 88(1):133–9. 88/1/133 [pii]. [PubMed: 18614733]
14. Trukova KP, Grutsch J, Lammersfeld C, Liepa G. Prevalence of vitamin d insufficiency among breast cancer survivors. *Nutr Clin Pract*. 2012; 27(1):122–8. 0884533611431461 [pii]. 10.1177/0884533611431461 [PubMed: 22227726]

15. Ansell D, Grabler P, Whitman S, Ferrans C, Burgess-Bishop J, Murray LR, et al. A community effort to reduce the black/white breast cancer mortality disparity in Chicago. *Cancer Causes Control*. 2009; 20(9):1681–8.10.1007/s10552-009-9419-7 [PubMed: 19688184]
16. Centers for Disease Control and Prevention /National Center for Health Statistics. [Accessed May 12, 2014] National Health and Nutrition Examination Survey Data. <http://www.cdc.gov/nchs/nhanes.htm>
17. Mares-Perlman JA, Klein BE, Klein R, Ritter LL, Fisher MR, Freudenheim JL. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. *The Journal of Nutrition*. 1993; 123(3):489–501. [PubMed: 8463852]
18. Centers for Disease Control and Prevention / National Center for Health Statistics. [Accessed December 16, 2014] National Health and Nutrition Examination Survey. <http://www.cdc.gov/nchs/tutorials/dietary/surveyorientation/dietarydataoverview/info2.htm>
19. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltayev N. A reference standard for the description of osteoporosis. *Bone*. 2008; 42(3):467–75.10.1016/j.bone.2007.11.001 [PubMed: 18180210]
20. Bonnick, S., editor. *Bone Densitometry in Clinical Practice*. New York, NY: Humana Press; 2010.
21. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2001; 12(6):438–44.10.1007/s001980170087
22. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 1997; 12(11):1761–8.10.1359/jbmr.1997.12.11.1761
23. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008; 26(7):1051–7.10.1200/JCO.2007.11.0726 [PubMed: 18309940]
24. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2005; 23(22):5126–37.10.1200/JCO.2005.07.097 [PubMed: 15983390]
25. Gibson, R. *Principles of Nutrition Assessment*. 2. New York: Oxford University Press; 2005.
26. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. *British journal of cancer*. 1999; 79(7–8):1179–81.10.1038/sj.bjc.6690188 [PubMed: 10098755]
27. Abdel-Razeq H, Awidi A. Bone health in breast cancer survivors. *J Cancer Res Ther*. 2011; 7(3): 256–63.10.4103/0973-1482.87006 [PubMed: 22044804]
28. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007; 25(5):486–92.10.1200/JCO.2006.08.8617 [PubMed: 17200148]
29. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *The lancet oncology*. 2008; 9(1):45–53.10.1016/S1470-2045(07)70385-6 [PubMed: 18083636]
30. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). *J Bone Miner Res*. 2006; 21(8):1215–23.10.1359/jbmr.060508 [PubMed: 16869719]

31. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. *Bone*. 2007; 40(1):205–10.10.1016/j.bone.2006.06.027 [PubMed: 16904960]
32. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. *J Bone Miner Res*. 2005; 20(2):185–94.10.1359/JBMR.041007 [PubMed: 15647811]
33. Cauley JA, Lui LY, Stone KL, Hillier TA, Zmuda JM, Hochberg M, et al. Longitudinal study of changes in hip bone mineral density in Caucasian and African-American women. *Journal of the American Geriatrics Society*. 2005; 53(2):183–9.10.1111/j.1532-5415.2005.53101.x [PubMed: 15673339]
34. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. *The Journal of clinical endocrinology and metabolism*. 2008; 93(3):861–8.10.1210/jc.2007-1876 [PubMed: 18160467]
35. Wagner DR, Heyward VH. Measures of body composition in blacks and whites: a comparative review. *The American journal of clinical nutrition*. 2000; 71(6):1392–402. [PubMed: 10837277]
36. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, et al. Resistance to bone resorbing effects of PTH in black women. *J Bone Miner Res*. 1997; 12(6):958–66.10.1359/jbmr.1997.12.6.958 [PubMed: 9169356]
37. Finkelstein JS, Sowers M, Greendale GA, Lee ML, Neer RM, Cauley JA, et al. Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. *The Journal of clinical endocrinology and metabolism*. 2002; 87(7):3051–6. [PubMed: 12107200]
38. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. *The New England journal of medicine*. 2013; 369(21):1991–2000.10.1056/NEJMoa1306357 [PubMed: 24256378]
39. Lloyd JT, Alley DE, Hawkes WG, Hochberg MC, Waldstein SR, Orwig DL. Body mass index is positively associated with bone mineral density in US older adults. *Arch Osteoporos*. 2014; 9(1):175.10.1007/s11657-014-0175-2 [PubMed: 24664472]
40. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *Jama*. 2012; 307(5):491–7. jama.2012.39 [pii]. 10.1001/jama.2012.39 [PubMed: 22253363]
41. Sheean PM, Hoskins K, Stolley M. Body composition changes in females treated for breast cancer: a review of the evidence. *Breast Cancer Res Treat*. 2012; 135(3):663–80.10.1007/s10549-012-2200-8 [PubMed: 22903689]
42. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. *Jama*. 2014; 311(8):806–14.10.1001/jama.2014.732 [PubMed: 24570244]
43. Wilkins CH, Goldfeder JS. Osteoporosis screening is unjustifiably low in older African-American women. *Journal of the National Medical Association*. 2004; 96(4):461–7. [PubMed: 15101666]
44. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN Task Force Report: Bone Health in Cancer Care. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2009; 7 (Suppl 3):S1–32. quiz S3–5. [PubMed: 19555589]
45. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risidronate: the SABRE trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010; 28(6):967–75.10.1200/JCO.2009.24.5902 [PubMed: 20065185]
46. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN Task Force Report: Bone Health In Cancer Care. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2013; 11 (Suppl 3):S1–50. quiz S1. [PubMed: 23997241]

Table 1

Baseline clinical characteristics of African-American breast cancer survivors and their sex, age, race, and body mass index matched non-breast cancer controls from NHANES 2007–2010 (n=101 pairs)^{ab}

Characteristics	Mean ± SD or n (% of sample)		P Value
	Breast cancer n=101	Non-breast cancer n=101	
Age (years)	54.6 ± 9.8	54.7 ± 9.8	0.695
Race–African American	101 (100%)	101 (100%)	1.000
Weight (kg)	95.4 ± 16.9	94.5 ± 15.5	0.422
Body mass index (kg/m ²)	35.8 ± 5.3	35.8 ± 5.2	0.603
25–<30	8 (8%)	10 (10%)	0.918
30–<35	46 (45%)	45 (44%)	
35–<40	26 (26%)	23 (23%)	
>=40	21 (21%)	23 (23%)	
Education level			
High school or less	31 (31%)	53 (52%)	0.0002
Some college	31 (31%)	34 (34%)	
College graduate or graduate degree	39 (39%)	14 (14%)	
Employment			
Paid work	49 (48%)	56 (55%)	0.0294
Not working	37 (37%)	42 (42%)	
Out of work	13 (13%)	3 (3%)	
Other	2 (2%)	0 (0%)	
Health insurance, n (%)			
None	5 (5%)	17 (17%)	0.0135
Public	42 (42%)	35 (35%)	
Private	48 (47%)	48 (47%)	
Other	6 (6%)	1 (1%)	
Co-morbid conditions			
Hypertension	58 (57%)	65 (64%)	0.360
Diabetes	24 (24%)	25 (25%)	1.0

^a NHANES=National Health and Nutrition Examination Survey.

^b Breast cancer survivors and non-breast cancer counterparts were matched on sex, age (within one year), race (African-American), and body mass index (within 2 kg/m²).

Table 2

Bone health characteristics and dietary intake factors of African-American breast cancer survivors and their age, race, and body mass index matched non-breast cancer controls from NHANES 2007–2010 (n=101 pairs)^{ab}

Characteristics	Mean ± SD or n (% of sample)		P Value
	Breast cancer n=101	Non-breast cancer n=101	
Femoral neck BMD (g/cm ²) ^c	0.85 ± 0.15	0.91 ± 0.14	0.007
Total Femur BMD (g/cm ²) ^d	1.01 ± 0.13	1.00 ± 0.14	0.348
Femoral neck T-score ^e	−0.05 ± 1.25	0.40 ± 1.17	0.007
Low bone mass ^f	16 (16%)	10 (10%)	0.263
Osteoporosis ^g	1 (1%)	0 (0%)	
Energy intake (kcal/d)	2138 ± 1183	1750 ± 697	0.007
Total calcium intake (mg/d)	1001 ± 638	837 ± 597	0.067
Dietary (mg/d)	797 ± 512	677 ± 389	0.047
Supplement (mg/d)	204 ± 340	417 ± 632	0.097
Total calcium intake ≥1200 mg/d	32 (32%)	16 (16%)	0.020
Total vitamin D intake (IU/d)	340 ± 240	303 ± 468	0.423
Dietary (IU/d)	123 ± 107	128 ± 124	0.982
Supplement (IU/d)	217 ± 220	551 ± 668	0.010
Total vitamin D intake ≥600 IU/d	20%	12%	0.117

^aNHANES=National Health and Nutrition Examination Survey.

^bBreast cancer survivors and non-breast cancer controls were matched on sex, age (within one year), race (African-American), and body mass index (within 2 kg/m²).

^cLunar femoral neck BMD values for breast cancer patients were converted to Hologic values (g/cm²) to allow comparison across scanning devices, using the following equation:

$$\text{Hologic femoral neck BMD} = (\text{Lunar femoral neck BMD} - 0.045) / 1.158$$

^dLunar total femur BMD values for breast cancer patients were converted to Hologic total Femur values (g/cm²) to allow comparison across scanning devices, using the following equation:

$$\text{Hologic total femur BMD} = (\text{Lunar total femur BMD} - 0.038) / 1.030$$

^eThe reference value to calculate the T-score was based on healthy young adults from NHANES III

^fLow bone mass is defined as a BMD value between 1.0–2.5 SD below the average value for young healthy women (T-score −1.0 to −2.5 SD).

^gOsteoporosis is defined as a BMD value 2.5 standard deviations (SD) or more below the average value for young healthy women (a T-score of <−2.5 SD)

Table 3

Bone health characteristics and dietary intake factors of African-American breast cancer survivors prescribed adjuvant hormone therapies and their age, race, and body mass index matched non-breast cancer controls from NHANES 2007–2010 (n=45 pairs)^{abc}

Characteristics	Mean ± SD or n (% of sample)		P Value
	Breast cancer n=45	Non-breast cancer n=45	
Femoral neck BMD (g/cm ²) ^c	0.85 ± 0.11	0.89 ± 0.15	0.109
Total Femur BMD (g/cm ²) ^d	1.00 ± 0.12	1.00 ± 0.16	0.909
Femoral neck T-score ^e	−0.05 ± 0.93	0.28 ± 1.22	0.108
Low bone mass ^f	8 (18%)	6 (13%)	0.754
Osteoporosis ^g	0 (0%)	0 (0%)	NA
Energy intake (kcal/d)	2047 ± 1242	1751 ± 653	0.128
Total calcium intake (mg/d)	1054 ± 631	793 ± 446	0.033
Dietary (mg/d)	772 ± 535	695 ± 428	0.359
Supplement (mg/d)	282 ± 391	97 ± 202	0.014
Total calcium intake ≥1200 mg/d	16 (36%)	8 (18%)	0.134
Total vitamin D intake (IU/d)	393 ± 214	291 ± 319	0.080
Dietary (IU/d)	116 ± 104	157 ± 138	0.224
Supplement (IU/d)	277 ± 217	134 ± 279	0.013
Total vitamin D intake ≥600 IU/d	11 (22%)	7 (16%)	0.607

^aNHANES=National Health and Nutrition Examination Survey.

^bBreast cancer survivors and non-breast cancer controls were matched on sex, age (within one year), race (African-American), and body mass index (within 2 kg/m²).

^cThese analyses were further restricted to women who were currently or previously prescribed aromatase inhibitors or prescribed tamoxifen premenopausally.

^dLunar femoral neck BMD values for breast cancer patients were converted to Hologic values (g/cm²) to allow comparison across scanning devices, using the following equation:

$$\text{Hologic femoral neck BMD} = (\text{Lunar femoral neck BMD} - 0.045) / 1.158$$

^eLunar total Femur BMD values for breast cancer patients were converted to Hologic total Femur values (g/cm²) to allow comparison across scanning devices, using the following equation:

$$\text{Hologic total femur BMD} = (\text{Lunar total femur BMD} - 0.038) / 1.030$$

^fThe reference value to calculate the T-score was based on healthy young adults from NHANES III

^gLow bone mass is defined as a BMD value between 1.0–2.5 SD below the average value for young healthy women (T-score −1.0 to −2.5 SD).

^hOsteoporosis is defined as a BMD value 2.5 standard deviations (SD) or more below the average value for young healthy women (a T-score of < −2.5 SD)